RBFC
ALXN

Roman Butler Fullerton & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Roman Butler Fullerton & Co’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,450
Closed -$331K – 182
2019
Q1 		$331K Buy
+2,450
New +$305K 0.23% 135

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Roman Butler Fullerton & Co's ALXN Position: Q2 2019 in Review

Roman Butler Fullerton & Co sold out of Alexion Pharmaceuticals (ALXN) in Q2 2019, closing a stake of 2,450 shares — an estimated $331K sold.

Roman Butler Fullerton & Co first reported a position in ALXN in Q1 2019 and held it in 1 quarter. The position peaked at $331K in Q1 2019. 636 funds tracked by Wall St. Rank hold ALXN as of Q2 2019.

  • Roman Butler Fullerton & Co reported no remaining Alexion Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Roman Butler Fullerton & Co sold 2,450 Alexion Pharmaceuticals shares in Q2 2019, an estimated $331K.
  • Roman Butler Fullerton & Co first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Roman Butler Fullerton & Co's Alexion Pharmaceuticals position peaked at $331K in Q1 2019.
  • 636 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2019.

Based on Roman Butler Fullerton & Co's 13F filing for Q2 2019, filed 22 Jul 2019.